Myovant Sciences Shares Outstanding 2017-2022 | MYOV

Myovant Sciences shares outstanding from 2017 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Myovant Sciences Annual Shares Outstanding
(Millions of Shares)
2022 93
2021 90
2020 86
2019 67
2018 60
2017 49
2016 37
Myovant Sciences Quarterly Shares Outstanding
(Millions of Shares)
2022-06-30 95
2022-03-31 93
2021-12-31 93
2021-09-30 92
2021-06-30 92
2021-03-31 90
2020-12-31 90
2020-09-30 90
2020-06-30 89
2020-03-31 86
2019-12-31 89
2019-09-30 89
2019-06-30 76
2019-03-31 67
2018-12-31 68
2018-09-30 67
2018-06-30 63
2018-03-31 60
2017-12-31 60
2017-09-30 59
2017-06-30 59
2017-03-31 49
2016-12-31 54
2016-09-30 43
2016-06-30 41
2016-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.693B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.286B 9.60
GSK (GSK) United Kingdom $71.707B 8.61
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.077B 18.55
Biohaven Pharmaceutical Holding (BHVN) United States $10.582B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.645B 0.00
Arcus Biosciences (RCUS) United States $1.982B 38.68
Emergent Biosolutions (EBS) United States $1.465B 8.49
Zymeworks (ZYME) Canada $0.405B 0.00
Enzo Biochem (ENZ) United States $0.132B 0.00
Gelesis Holdings (GLS) United States $0.101B 0.00
Ambrx Biopharma (AMAM) United States $0.099B 0.00
SQZ Biotechnologies (SQZ) United States $0.096B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00